| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 347.17M | 256.21M | 133.88M | 179.48M | 211.78M | 185.20M |
| Gross Profit | 38.37M | 26.52M | -21.96M | 17.70M | 19.03M | 44.87M |
| EBITDA | -11.03M | -24.09M | -26.83M | 4.23M | -7.55M | 30.92M |
| Net Income | -16.43M | -24.71M | -34.43M | -170.00K | -17.10M | 2.46M |
Balance Sheet | ||||||
| Total Assets | 276.07M | 256.83M | 282.83M | 179.21M | 184.55M | 228.03M |
| Cash, Cash Equivalents and Short-Term Investments | 134.76M | 59.72M | 78.03M | 55.53M | 108.16M | 74.97M |
| Total Debt | 6.98M | 66.07M | 78.09M | 7.59M | 9.62M | 61.64M |
| Total Liabilities | 86.05M | 123.41M | 139.02M | 35.20M | 53.92M | 93.79M |
| Stockholders Equity | 187.99M | 129.94M | 138.46M | 144.01M | 130.63M | 134.24M |
Cash Flow | ||||||
| Free Cash Flow | 13.26M | -43.13M | -34.36M | 438.00K | 6.16M | 12.92M |
| Operating Cash Flow | 14.54M | -31.50M | -33.82M | 3.39M | 6.46M | 16.70M |
| Investing Cash Flow | -24.82M | 1.30M | 27.81M | -24.33M | -5.54M | -2.67M |
| Financing Cash Flow | 50.85M | 816.00K | 29.04M | 8.56M | -7.49M | -9.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
53 Neutral | HK$305.92M | -53.11 | -2.51% | ― | -1.40% | -128.66% | |
53 Neutral | HK$102.00M | -3.25 | -16.65% | 20.83% | -27.59% | -396.23% | |
53 Neutral | HK$123.00M | -4.34 | -25.91% | ― | 3.45% | -339.07% | |
49 Neutral | HK$380.24M | -5.56 | -9.91% | ― | 106.55% | 63.20% | |
45 Neutral | HK$455.61M | -7.71 | -4.97% | 2.25% | -35.13% | -11.52% | |
39 Underperform | HK$361.24M | -56.78 | -7.88% | ― | 9.79% | 89.05% |
Yues International Holdings Group Limited has announced that its indirect wholly owned subsidiary, Jiangxi Le Lao Hao Traditional Chinese Medicine Industry Technology Development Co., Ltd., has entered into a construction agreement with Fuzhou Chuanghong Construction Engineering Co., Ltd. for the development of the Jiangxi Le Lao Hao Traditional Chinese Medicine Logistics Industrial Park Project in Dongxiang District, Fuzhou City, Jiangxi Province, with a total planned construction area of about 27,238 square metres on land designated for warehousing and hotel uses. The project, with a construction contract sum of approximately RMB24.65 million, constitutes a discloseable transaction under Hong Kong listing rules and marks a concrete step in advancing the group’s logistics and industrial park footprint in the traditional Chinese medicine supply chain, potentially strengthening its operational infrastructure and positioning in this specialised sector.
The most recent analyst rating on (HK:1529) stock is a Hold with a HK$0.56 price target. To see the full list of analyst forecasts on Yues International Holdings Group Limited stock, see the HK:1529 Stock Forecast page.
Yues International Holdings Group Limited has relocated its principal place of business in Hong Kong to Room 2806, 28/F, China Resources Building, 26 Harbour Road, Wanchai, effective 14 January 2026, while keeping its telephone, facsimile and website details unchanged. The move represents an administrative change rather than a shift in strategy, and signals continuity in the company’s operations and communications with stakeholders, with the existing board and governance structure remaining intact.
The most recent analyst rating on (HK:1529) stock is a Hold with a HK$0.51 price target. To see the full list of analyst forecasts on Yues International Holdings Group Limited stock, see the HK:1529 Stock Forecast page.
Yues International Holdings Group Limited has appointed Mr. Yueh Chueh-Hsin as an executive director effective from December 8, 2025. Mr. Yueh, a 14th-generation successor of the Le Family Tong Ren Tang traditional pharmacy, brings extensive experience in TCM research and the health industry. His appointment is expected to enhance the company’s strategic planning and investment decisions, especially in integrating heritage brands with modern biotechnology and digital technologies. This move could strengthen the company’s market position and offer new opportunities for growth and innovation in the TCM sector.
The most recent analyst rating on (HK:1529) stock is a Hold with a HK$0.53 price target. To see the full list of analyst forecasts on Yues International Holdings Group Limited stock, see the HK:1529 Stock Forecast page.
Yues International Holdings Group Limited has announced the composition of its board of directors, which includes six members with specific roles and functions. The board consists of executive directors and independent non-executive directors, highlighting the company’s governance structure. This announcement outlines the membership of the company’s three board committees, which are the Audit Committee, Remuneration Committee, and Nomination Committee, reflecting the company’s commitment to structured governance and oversight.
The most recent analyst rating on (HK:1529) stock is a Hold with a HK$0.53 price target. To see the full list of analyst forecasts on Yues International Holdings Group Limited stock, see the HK:1529 Stock Forecast page.
Yues International Holdings Group Limited, a company incorporated in the Cayman Islands, announced a discloseable transaction involving the sale of approximately 30% equity interests in a subsidiary. This transaction, valued at RMB30 million, involves a sale and purchase agreement with an independent third party, Mr. Zeng Xianyong. The disposal is classified as a discloseable transaction under the Listing Rules, requiring an announcement but exempt from shareholder approval. The transaction is structured to ensure the Target Group remains under the control of Yues International Holdings Group Limited, with specific payment terms and restrictions on the purchaser until the consideration is fully settled.
The most recent analyst rating on (HK:1529) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Yues International Holdings Group Limited stock, see the HK:1529 Stock Forecast page.